Corcept Therapeutics (CORT) Receivables - Other (2019 - 2025)

Corcept Therapeutics has disclosed Receivables - Other across 7 years of filings, most recently posting $4.1 million for Q4 2025.

• Receivables - Other for Q4 2025 came in at $4.1 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.1 million (changed 0.0% YoY), and the FY2025 annual result was $4.1 million, changed 0.0% from the prior year.
• Receivables - Other came in at $4.1 million for Q4 2025 at Corcept Therapeutics, up from $3.9 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $18.2 million in Q1 2025 to a low of $900000.0 in Q3 2022.
• The 5-year median for Receivables - Other is $2.9 million (2024), against an average of $5.6 million.
• Peak annual rise in Receivables - Other reached 1455.56% in 2023, while the deepest fall reached 87.86% in 2023.
• Corcept Therapeutics' Receivables - Other stood at $1.4 million in 2021, then soared by 900.0% to $14.0 million in 2022, then slumped by 87.86% to $1.7 million in 2023, then surged by 141.18% to $4.1 million in 2024, then dropped by 0.0% to $4.1 million in 2025.
• The last three Receivables - Other figures came in at $4.1 million (Q4 2025), $3.9 million (Q3 2025), and $4.1 million (Q2 2025), per Business Quant data.